Sign In
Buy PRME
$2.92
-0.100 (-3.31%)
At Close: Jul 31, 2026
Liminatus Pharma (NASDAQ:LIMN) versus Prime Medicine (NASDAQ:PRME) Head to Head Comparison
02:38am, Sunday, 23'rd Nov 2025
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) are both small-cap manufacturing companies, but which is the better investment? We will contrast t
Analyzing Prime Medicine (NASDAQ:PRME) and Liminatus Pharma (NASDAQ:LIMN)
02:20am, Tuesday, 18'th Nov 2025
Liminatus Pharma (NASDAQ: LIMN - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will compare the t
Prime Medicine, Inc. (PRME) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease Transcript
02:51pm, Wednesday, 12'th Nov 2025
Prime Medicine, Inc. ( PRME ) Discusses Liver Disease Franchise Strategy With Focus on Wilson Disease November 12, 2025 8:00 AM EST Company Participants Gregory Dearborn Allan Reine - CEO & Director M
Prime Medicine to Present at Jefferies Global Healthcare Conference
08:00am, Tuesday, 11'th Nov 2025
CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
10:21am, Friday, 07'th Nov 2025
-- New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as de
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates
09:11am, Friday, 07'th Nov 2025
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.44 per share a year ago.
Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
07:00am, Friday, 07'th Nov 2025
-- New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as de
Prime Medicine Appoints Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer
08:01am, Monday, 03'rd Nov 2025
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy
04:01pm, Thursday, 30'th Oct 2025
CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
Inhibikase Therapeutics (NASDAQ:IKT) versus Prime Medicine (NASDAQ:PRME) Head-To-Head Contrast
01:32am, Wednesday, 22'nd Oct 2025
Prime Medicine (NASDAQ: PRME - Get Free Report) and Inhibikase Therapeutics (NASDAQ: IKT - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will comp
Prime Medicine to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 07'th Oct 2025
CAMBRIDGE, Mass., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
Prime Drink Group Provides Bi-Weekly MCTO Status Report
06:30pm, Friday, 12'th Sep 2025
MONTREAL, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to its news releases dated July 30, August 15, and August 29,
Prime Medicine, Inc. (PRME) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
05:38pm, Monday, 08'th Sep 2025
Prime Medicine, Inc. (NASDAQ:PRME ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:05 PM EDT Company Participants Allan Reine - CEO & Director Conference Call Participants
Prime Drink Group Terminates Rights Offering and Announces Private Placement
06:30pm, Thursday, 04'th Sep 2025
MONTREAL, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that it has terminated its previously disclosed rights offering and that i
Prime Medicine, Inc. (PRME) Presents At Citi's Biopharma Back To School Conference Transcript
08:07pm, Tuesday, 02'nd Sep 2025
Prime Medicine, Inc. (NASDAQ:PRME ) Citi's Biopharma Back to School Conference September 2, 2025 4:45 PM EDT Company Participants Allan Reine - CEO & Director Conference Call Participants Samantha Sem
